CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study
Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.
Aim(s): The aim was to discern which criterion (Choi vs RECIST) best captures sunitinib’s activity in patients with advanced well-differentiated PanNET treated with sunitinib.
Materials and methods: A multicenter, prospective study (NCT02841865) was conducted in 10 Spanish centers of the GETNE group between 2012 and 2017. Eligibility criteria included availability of serial image studies, with arterial and portal phase, within the 4 weeks prior to initiating sunitinib, and at least every 6 months until progression. Choi and RECIST v1.1 were centrally analyzed
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.